https://www.fiercebiotech.com/biotech/protalix-chiesi-edge-close-to-potential-fabry-disease-approval
0
0
5/28/20 at 11:50am
Organization
FierceBiotech
Author
Ben Adams
32 words
0
Comments
Israeli biotech Protalix BioTherapeutics and partner Chiesi have sent off their Biologics License Application for rare disease hopeful pegunigalsidase alfa to the FDA.
You are the first to view
Create an account
or login to join the discussion